Drug Profile
MDL 74366
Latest Information Update: 03 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Anti-ischaemics; Antiarrhythmics; Ischaemic heart disorder therapies; Vitamins
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Myocardial ischaemia
Most Recent Events
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 21 Dec 1994 Preclinical development for Myocardial ischaemia in USA (Unknown route)